NATCO pharma is a Hyderabad-based pharmaceutical company which became famous when the Indian Patent office used the WTO-TRIPS 2006 agreement to give it permission to replicate and produce a generic version of Bayer’s cancer drug Nexavar which would bring down the price of the drug by 97%. This was the first instance of a country giving a compulsory licence and led to protracted legal stand-off which finally ended in NATCO’s favour.
India vs Big Pharma: Compulsory licence for leukaemia drug sought
Despite compulsory licensing, generic cancer drug too costly for the poor
Glaxo patent on breast cancer drug revoked
'Compulsory licence verdict a triumph for humanity'
Experts believe that this case will set a precedent for all future legal tangles between Big Pharma and the country as a marker of how cases pertaining to drug patents will be played out in the country.
Novartis not optimistic about Supreme Court verdict
Leading lawyer calls India's pharma sector 'hip and hapenning'
Govt set to hand out three more compulsory licenses for cancer drugs
Judges tell Novartis at Rs 1.2 lakh a month, drugs too expensive for them!
Novartis claims to have distributed free drugs worth Rs 7,500 cr
SC asks Novartis to reduce drug price - again!
Intellectual property board hears Bayer vs compulsory licencing case, verdict awaited
Cancelling compulsory license won't be against public interest: Bayer
"Novartis win will have an adverse impact on the access to treatment"
Pathbreaking case - India Vs Big Pharma - in Supreme Court tomorrow
US wants India to increase cancer drug prices
Cipla to continue slashing cancer drug prices
Bayer challenges 'compulsory license' ruling
'Compulsory licence' to Natco will bring down cost of cancer drug by 97%
Compulsory licensing effect: Cipla slashes price of generic cancer drug by 80%!
Roche Holding plans to launch two blockbuster cut-price cancer drugs in India
India vs Big Pharma: Compulsory licence for leukaemia drug sought
Despite compulsory licensing, generic cancer drug too costly for the poor
Glaxo patent on breast cancer drug revoked
'Compulsory licence verdict a triumph for humanity'
Experts believe that this case will set a precedent for all future legal tangles between Big Pharma and the country as a marker of how cases pertaining to drug patents will be played out in the country.
Novartis not optimistic about Supreme Court verdict
Leading lawyer calls India's pharma sector 'hip and hapenning'
Govt set to hand out three more compulsory licenses for cancer drugs
Judges tell Novartis at Rs 1.2 lakh a month, drugs too expensive for them!
Novartis claims to have distributed free drugs worth Rs 7,500 cr
SC asks Novartis to reduce drug price - again!
Intellectual property board hears Bayer vs compulsory licencing case, verdict awaited
Cancelling compulsory license won't be against public interest: Bayer
"Novartis win will have an adverse impact on the access to treatment"
Pathbreaking case - India Vs Big Pharma - in Supreme Court tomorrow
US wants India to increase cancer drug prices
Cipla to continue slashing cancer drug prices
Bayer challenges 'compulsory license' ruling
'Compulsory licence' to Natco will bring down cost of cancer drug by 97%
Compulsory licensing effect: Cipla slashes price of generic cancer drug by 80%!
Roche Holding plans to launch two blockbuster cut-price cancer drugs in India
